Eli Lilly & Co. and Novo Nordisk A/S are leveraging a fresh weapon in their crackdown against copycat versions of their blockbuster weight loss drugs.
The two pharmaceutical giants over the last year have filed 10 cases against compounders and telehealth companies with BBB National Programs’ National Advertising Division, a self-regulatory body providing dispute resolution over advertising claims. The non-government group has been around since 1971, settling disagreements over products from bathroom cleaners to infant formula — but the GLP-1 drugmakers turned to it relatively recently.
It’s another avenue in the aggressive fight to rein in unapproved versions of their powerful obesity and diabetes GLP-1 drugs, adding to a string of federal lawsuits and cease-and-desist letters filed against copycats in the last two years. The latest endeavor has so far proven successful as compounders have voluntarily discontinued or modified disputed claims.
The stakes are clear: Lilly’s tirzepatide and Novo’s semaglutide are among the only FDA-cleared GLP-1 drugs. Lilly’s franchise reached $40 billion in sales, while Novo’s products generated $35 billion last year.
“They’re using a lot of arsenals,” said Alan Minsk, chair of the food and drug practice at Arnall Golden Gregory LLP. “These are big bucks for the companies and they’re trying to use all of their tools that they’ve got.”
The series of challenges largely began after the FDA determined that branded GLP-1s are now available following a shortage period, effectively prohibiting mass production of cheaper copies that have been used by at least a million patients. Still, compounders continue to make personalized versions.
“We will continue to work with law enforcement and regulators to help address illegal activity,” a Novo spokesperson said in an email, sharing the company has filed 130 federal lawsuits and five challenges with the NAD. “Novo Nordisk views NAD challenges as an important forum to bring complaints against companies making false and misleading claims about unapproved compounded drugs.”
Lilly, which has also filed dozens of federal lawsuits and at least five cases with the NAD, similarly credited the division as “an independent authority whose mission is to build consumer trust in advertising.”
Each company challenged by Novo or Lilly did not respond to requests for comment.
Speedier Pathway
The forum has long served as a faster and more cost-effective process compared to litigation, which can drag on for years.
Unlike legal proceedings, the burden is on the defendant, or the advertiser, to demonstrate it has a reasonable basis to make the claim at issue. The division assigns an attorney to review a case, confer with parties for a briefing period, and ultimately draft a decision or recommendation.
The process, however, is voluntary. Companies can file a challenge, but an advertiser isn’t required to participate in the case or follow recommendations. While the NAD doesn’t hold any legal authority, it can escalate the matter to regulators such as the FDA, Federal Trade Commission, or state attorneys general for potential enforcement. It may also report the ad to social media platforms where it runs.
“It’s been interesting to see this case package come from the GLP-1 manufacturers,” Phyllis Marcus, vice president of the NAD. “They present almost the full suite of advertising techniques. You’ve got social media, you’ve got influencers, you’ve got health claims, you’ve got one of the hottest drugs on the market.”
Advertisers can appeal decisions to a board of academics and brand representatives.
“The options vary a lot in terms of cost, timeframe to a resolution, and effectiveness,” said Ricardo Carvajal, a director at Hyman, Phelps & McNamara P.C., representing advertisers. “But at the end of the day, we’re talking about a matter of months to get to a final resolution in the form of an NAD case decision.”
Lilly’s latest challenge targeted Noom Inc.’s “A Smaller Dose. A Smarter Start” tagline for its compounded GLP-1s. The NAD determined the company failed to provide adequate support for its message. Noom disagreed with the conclusion but still agreed to drop or modify the claim.
Novo’s latest case pressured Willow Health Services Inc. to permanently discontinue certain safety and efficacy claims for its compounded semaglutide. The move came after the NAD referred the matter to the FTC and state attorneys general when Willow failed to provide a statement indicating whether it would comply with recommendations.
Seeking Enforcement
The rise in challenges comes amid a lighter regulatory touch from the FDA.
“FDA is likely receiving many trade complaints,” said Dara Katcher Levy, a director at Hyman, counseling companies on product communications. “That’s probably why companies are now moving toward the NAD option of bringing their complaints. FDA’s warning letters, at least in this space for the telehealth and compounders, have been very narrow.”
While compounded drug ads can’t be false or misleading under federal laws, they still don’t face the same kind of government sign-off as brand-name treatments. Still, the FDA has increasingly targeted them in the last year with more than 100 warning letters sent to companies regarding misbranded claims.
But even with increased oversight, the FDA’s warnings have largely focused on a limited set of claims such as active ingredients, branding, and product performance.
“The enforcement has really been focused on what these websites shouldn’t say, and that absolutely is needed,” said Ashwin Chetty, a doctor of medicine candidate at Yale School of Medicine, who studied compounded GLP-1 ads. “But there should also be some guidance and enforcement on what these websites should be saying as well.”